Literature DB >> 510361

Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat.

P R Saxena, W I Cairo-Rawlins.   

Abstract

The effects of ergotamine on the tachycardia elicited by postganglionic stimulation of the cardioaccelerator nerve have been investigated in both intact and spinal (desmethylimipramine-pretreated) cats. Ergotamine (2.5--20 microgram kg-1) selectively antagonized the response to low-frequency (0.3--3 Hz) stimulation. The responses elicited by stimulation of the nerve with higher frequencies (greater than 10 Hz) either remained unaltered or were facilitatated by the drug. Pretreatment of the cats with pimozide (0.2 mg kg-1) completely antagonized the inhibitory effects of ergotamine on the sympathetic neuron. Although phentolamine (0.5 mg kg-1) did appear to attenuate the effects of ergotamine, the changes were, however, not statistically significant. Since the drug did not reduce the cardiac effects of isoprenaline or tyramine, it is concluded that ergotamine interferes with the release of noradrenaline from the cardioaccelerator nerve, mainly by stimulating the presynaptic dopaminergic receptors. This effect may be an important mechanism by which the drug causes bradycardia in almost all species regardless of the blood pressure response.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 510361     DOI: 10.1016/0014-2999(79)90479-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Carotid vascular effects of ergotamine and dihydroergotamine in the pig: no exclusive mediation via 5-HT1-like receptors.

Authors:  M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

2.  In vivo and in vitro dopaminergic effects of three ergoline fragments.

Authors:  J C Koons; J P Long; J G Cannon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-12       Impact factor: 3.000

3.  The effects of nitroglycerin on exercise-induced regional myocardial contractile dysfunction are not diminished by pretreatment with dihydroergotamine.

Authors:  W Schneider; G Krumpl; N Mayer; G Raberger
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

4.  Effects of dihydroergotamine (DHE) on blood flow and metabolism in the underperfused myocardium in anaesthetized dogs.

Authors:  R Seitelberger; W Schütz; G Raberger
Journal:  Basic Res Cardiol       Date:  1984 Jul-Aug       Impact factor: 17.165

5.  Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors.

Authors:  A H Bom; J P Heiligers; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

6.  Pharmacological characterization of ergotamine-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  Luis E Cobos-Puc; Carlos M Villalón; Araceli Sánchez-López; Martha B Ramírez-Rosas; Jair Lozano-Cuenca; Heinz H Pertz; Tilo Görnemann; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-09       Impact factor: 3.000

Review 7.  Post-triptan era for the treatment of acute migraine.

Authors:  Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2004-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.